TOKYO -- Japanese drugmaker Shionogi said Monday that preliminary laboratory studies suggest its COVID-19 tablet inhibits the severity of infections from the highly transmissible omicron variant, providing optimism that the low-cost treatment may help prevent a surge in hospitalizations.
